Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AVROBIO, Inc.

http://www.avrobio.com/

Latest From AVROBIO, Inc.

Keeping Track: TGT’s Ukoniq Is Latest PI3K Inhibitor To Fall; GSK’s Daprodustat, Aeglea’s Pegzilarginase Headline Submissions

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

US FDA Performance Tracker Approvals

US FDA’s 2022 Novel Agent Actions Suggest Acceleration In Use Of Complete Response Letters

COVID does not appear to be a driving factor, and letters are split almost equally between clinical and quality concerns.

Complete Response Letters Drug Approval Standards

Sangamo Can Take Lead In Fabry Gene Therapy

Avrobio dropping out of the race means Sangamo can take advantage but its gene therapy must show long-term efficacy in patients not receiving enzyme replacement therapy.

Rare Diseases Research & Development

Stock Watch: 2022 Starts Badly For Biotech

A slow start to the year in health care is usually tempered by announcements that build up to investor conference season. However, early 2022’s plethora of negative announcements may continue biotech’s unloved status of 2021.

Stock Watch Clinical Trials
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
    • Drug Delivery
      • Macromolecule
  • In Vitro Diagnostics
    • Therapeutic Drug Monitoring
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
UsernamePublicRestriction

Register